PROGRAM (subject to change)

8:15-8:45 am  Registration and Breakfast
8:45-9:00 am  Welcome/Introduction  
Jason Gotlib, MD
9:00-9:40 am  Myelodysplastic Syndromes  
Peter Greenberg, MD
9:40-10:20 am  Multiple Myeloma/Amyloidosis  
Michaela Liedtke, MD
10:20-10:40 am  Break
10:40-11:20 am  Bleeding and Thrombotic Disorders  
Lawrence Leung, MD
11:20-12:00 pm  Myeloproliferative Neoplasms  
Jason Gotlib, MD
12:00-1:00 pm  Lunch
1:00-1:40 pm  Red Blood Cell Disorders and Iron Homeostasis  
Stanley Schrier, MD
1:40-2:20 pm  Chronic Lymphocytic Leukemia  
Steven Coutre, MD
2:20-2:40 pm  Break
2:40-3:20 pm  Acute Myeloid Leukemia  
Bruno Medeiros, MD
3:20-4:00 pm  Hodgkin and Non-Hodgkin Lymphomas  
Ranjana Advani, MD
4:00 pm  Adjourn

Opportunities for Q&A will be provided at the conclusion of each presentation.

FACULTY

All faculty are affiliated with Stanford University School of Medicine unless otherwise noted.

Jason Gotlib, MD  
Associate Professor of Medicine (Hematology)  
Course Director

Michaela Liedtke, MD  
Assistant Professor of Medicine (Hematology)  
Course Co-Director

Ranjana Advani, MD  
Saul A. Rosenberg Professor of Lymphoma

Steven Coutre, MD  
Professor of Medicine (Hematology), Emeritus

Peter Greenberg, MD  
Professor of Medicine (Hematology), Emeritus

Lawrence Leung, MD  
Maureen Lyles D’Ambrogio Professor of Medicine (Hematology)

Bruno C. Medeiros, MD  
Associate Professor of Medicine (Hematology)

Stanley Schrier, MD  
Professor of Medicine (Hematology), Emeritus

Faculty Disclosure

The Stanford University School of Medicine adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of faculty and commercial relationships will be made prior to the activity.

To register online, visit http://cme.stanford.edu/hematology/
STATEMENT OF NEED
This CME event led by the Stanford Division of Hematology seeks to fulfill the need of practicing hematologists/oncologists, nurse practitioners, physicians assistants, pharmacists and allied health care practitioners in the academic and community settings to increase the fund of knowledge in malignant and benign hematology by reviewing the latest data presented at the 56th Annual American Society of Hematology Meeting. The goal of the symposium is to optimize care of patients by incorporating the latest best practices in diagnosis and treatment highlighted at ASH.

TARGET AUDIENCE
This regional conference is designed to meet the educational needs of Hematologists, Oncologists, Nurse Practitioners, Physician Assistants, Nurses, and Pharmacists who care for patients with malignant and benign hematologic diseases.

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to review and evaluate data from the most recent clinical trials and develop strategies to:
• Evaluate new chemotherapy/biologic regimens for different subpopulations of acute myeloid leukemia patients based on clinical and genetic prognostic factors and determine how to apply them to treatment decisions
• Apply strategies to optimally utilize JAK inhibition and other novel agents in patients with myelofibrosis and other relevant myeloproliferative neoplasms based on the new prognostic models to risk stratify MPN patients
• Determine available therapeutic options for patients with low- or high-risk myelodysplastic syndromes, including those who are relapsed/ refractory to hypomethylating agents and utilize the IPSS-R prognostic scoring system and new mutation data to classify patients for treatment
• Identify best combination regimens and novel agents for relevant populations of myeloma patients, including transplant eligible vs. ineligible
• Evaluate differences in indications, dose, and safe use of oral anticoagulants and assess new experimental data regarding mechanisms of bleeding and thrombosis
• Implement BTK and PI3K inhibition, anti-CD30 antibody drug immunocconjugate therapy and other agents for the treatment of chronic lymphocytic leukemia and/or lymphomas, either alone or in combination with conventional therapies
• Incorporate new data for optimizing treatment of iron overload/deficiency and analyze the biologic pathways relevant to iron homeostasis, including inflammatory states; evaluate novel pre-clinical data related to hemoglobinopathies

ACCREDITATION
The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Stanford University School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The California Board of Registered Nursing recognizes that Continuing Medical Education (CME) is acceptable for meeting RN continuing education requirements; as long as the course is certified for AMA PRA Category 1 Credits™ (rn.ca.gov). Nurses will receive a Certificate of Attendance following this activity that may be used for license renewal.